Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 23

Related Articles by Review for PubMed (Select 19741148)

1.

Effectiveness of donepezil, rivastigmine, and (+/-)huperzine A in counteracting the acute toxicity of organophosphorus nerve agents: comparison with galantamine.

Aracava Y, Pereira EF, Akkerman M, Adler M, Albuquerque EX.

J Pharmacol Exp Ther. 2009 Dec;331(3):1014-24. doi: 10.1124/jpet.109.160028. Epub 2009 Sep 9.

2.

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.

Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, Clegg A.

Health Technol Assess. 2006 Jan;10(1):iii-iv, ix-xi, 1-160. Review.

4.

Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.

Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N.

Int J Technol Assess Health Care. 2002 Summer;18(3):497-507. Review.

PMID:
12391943
5.

A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.

Takeda A, Loveman E, Clegg A, Kirby J, Picot J, Payne E, Green C.

Int J Geriatr Psychiatry. 2006 Jan;21(1):17-28. Review.

PMID:
16323253
6.

Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence.

Lockhart IA, Mitchell SA, Kelly S.

Dement Geriatr Cogn Disord. 2009;28(5):389-403. doi: 10.1159/000255578. Epub 2009 Nov 6. Review.

7.

Non-enzymatic pretreatment of nerve agent (soman) poisoning: a brief state-of-the-art review.

van Helden HP, Joosen MJ, Philippens IH.

Toxicol Lett. 2011 Sep 25;206(1):35-40. doi: 10.1016/j.toxlet.2011.04.021. Epub 2011 Apr 28. Review.

PMID:
21554933
8.

The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.

Inglis F.

Int J Clin Pract Suppl. 2002 Jun;(127):45-63. Review.

PMID:
12139367
9.

Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.

Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE.

Clin Interv Aging. 2008;3(2):211-25. Review.

10.

[Are anti-dementia drugs worthwhile?].

Lang CJ.

MMW Fortschr Med. 2007 Sep 13;149 Suppl 3:85-9. Review. German. Erratum in: MMW Fortschr Med. 2008 Jan 17;149 Suppl 4:136. dosage error in text.

PMID:
17955784
11.

Drug therapy of dementia in elderly patients. A review.

Olsen CE, Poulsen HD, Lublin HK.

Nord J Psychiatry. 2005;59(2):71-7. Review.

PMID:
16195103
12.
13.
15.

Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.

Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J.

Drugs Aging. 2004;21(7):453-78. Review.

PMID:
15132713
16.

The role of oximes in the treatment of nerve agent poisoning in civilian casualties.

Marrs TC, Rice P, Vale JA.

Toxicol Rev. 2006;25(4):297-323. Review.

PMID:
17288500
17.

Cholinesterase inhibitors in the treatment of dementia.

Ellis JM.

J Am Osteopath Assoc. 2005 Mar;105(3):145-58. Review.

PMID:
15863734
18.

Cholinesterase inhibitor adjunctive therapy for cognitive impairment and depressive symptoms in older adults with depression.

McDermott CL, Gray SL.

Ann Pharmacother. 2012 Apr;46(4):599-605. doi: 10.1345/aph.1Q445. Epub 2012 Mar 13. Review.

PMID:
22414791
19.

[Cholinesterase inhibitors in the treatment of dementia--are they useful in clinical practice?].

Landmark K, Reikvam A.

Tidsskr Nor Laegeforen. 2008 Jan 31;128(3):294-7. Review. Norwegian.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk